Publications and Further Research Outputs
Peer-Reviewed Publications
Chalandon Y, Sbianchi G, Gras L, Koster L, Apperley J, Byrne J, Salmenniemi U, Sengeloev H, Aljurf M, Helbig G, Kinsella F, Choi G, Reményi P, Snowden JA, Robin M, Lenhoff S, Mielke S, Passweg J, Broers AEC, Kröger N, Yegin ZA, Tan SM, Hayden PJ, McLornan DP, Yakoub-Agha I, Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT)., Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT., American journal of hematology, 98, (1), 2023, p112-121
Waszczuk-Gajda A, Gras L, de Wreede LC, Sirait T, Illes A, Ozkurt ZN, Snowden JA, Arat M, Bulabois CE, Niederland J, Sever M, Paneesha S, Potter V, Gadisseur A, Chalopin T, Van Gorkom G, López JM, Kerre T, Drozd-Sokolowska J, Raj K, Hayden PJ, Beksac M, Yakoub-Agha I, McLornan DP, Schönland S., Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients-The DIADEM study from the chronic malignancies working party of the EBMT., Bone marrow transplantation, 2023
Beksac M, Hayden P., Upfront autologous transplantation still improving outcomes in patients with multiple myeloma., The Lancet. Haematology, 10, (2), 2023, pe80-e82
Drozd-Sokolowska J, Gras L, Zinger N, Zahrani MA, Passweg J, Byrne J, Ho A, Huang XJ, Kröger N, Mayer J, Russo D, De Becker A, Tbakhi A, Stamatoullas A, Valerius T, Hayden P, McLornan DP, Onida F, Scheid C, Robin M, Yakoub-Agha I., Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome unclassifiable - a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT., Bone marrow transplantation, 58, (2), 2023, p222-225
Polverelli N, Hernández-Boluda JC, Czerw T, Barbui T, D'Adda M, Deeg HJ, Ditschkowski M, Harrison C, Kröger NM, Mesa R, Passamonti F, Palandri F, Pemmaraju N, Popat U, Rondelli D, Vannucchi AM, Verstovsek S, Robin M, Colecchia A, Grazioli L, Damiani E, Russo D, Brady J, Patch D, Blamek S, Damaj GL, Hayden P, McLornan DP, Yakoub-Agha I., Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT., The Lancet. Haematology, 10, (1), 2023, pe59-e70
Robin M, de Wreede LC, Schroeder T, Stölzel F, Kröger N, Koster L, Platzbecker U, Finke J, Ganser A, Blaise D, Ciceri F, Maertens J, Labussière Wallet H, Wang J, Chevallier P, Passweg J, Cornelissen JJ, Nguyen S, Forcade E, Charbonnier A, Bonifazi F, Hayden P, McLornan DP, Yakoub-Agha I., Primary Cancer Matters in Therapy-related Myeloid Neoplasm Patients Receiving Allogeneic Hematopoietic Cell Transplantation: A Study From the Chronic Malignancies Working Party of the EBMT., Hemasphere, 7, (4), 2023, pe851
Vincent L, Gras L, Ceballos P, Finke J, Passweg J, Harel S, Rosinol L, Minnema M, Teipel R, van Doesum J, Hänel M, Lenain P, Botella-Garcia C, Koenecke C, Ducastelle S, Sanz J, Schroyens W, Zuckerman T, Monaco F, Koster L, de Wreede L, Hayden PJ, Schönland S, Yakoub-Agha I, Beksac M., Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT., Bone marrow transplantation, 57, (3), 2022, p499-501
Hernández-Boluda JC, Pereira A, Zinger N, Gras L, Martino R, Nikolousis E, Finke J, Chinea A, Rambaldi A, Robin M, Saccardi R, Natale A, Snowden JA, Tsirigotis P, Vallejo C, Wulf G, Xicoy B, Russo D, Maertens J, Daguindau E, Lenhoff S, Hayden P, Czerw T, McLornan DP, Yakoub-Agha I., Correction: Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT., Bone marrow transplantation, 57, (6), 2022, p1051
Forcade E, Chevret S, Finke J, Ehninger G, Ayuk F, Beelen D, Koster L, Ganser A, Volin L, Sengeloev H, Michallet M, Tischer J, Jindra P, Cascon MJP, Koc Y, Arat M, Tomaszewska A, Hayden P, de Witte T, Yakoub-Agha I, Kröger N, Robin M., Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant: a registry study from the Chronic Malignancies Working Party of the EBMT., Bone marrow transplantation, 57, (5), 2022, p768-774
Dholaria B, Radujkovic A, Estrada-Merly N, Sirait T, Kim S, Hernández-Boluda JC, Czerw T, Hayden PJ, Kansagra A, Ho VT, Nishihori T, Shaughnessy P, Scott B, Nakamura R, Oran B, Kharfan-Dabaja M, Savani BN, McLornan D, Yakoub-Agha I, Saber W., Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: A combined CIBMTR/CMWP of EBMT analysis., British journal of haematology, 198, (4), 2022, p785-789
Czerw T, Iacobelli S, Malpassuti V, Koster L, Kröger N, Robin M, Maertens J, Chevallier P, Watz E, Poiré X, Snowden JA, Kuball J, Kinsella F, Blaise D, Reményi P, Mear JB, Cammenga J, Rubio MT, Maury S, Daguindau E, Finnegan D, Hayden P, Hernández-Boluda JC, McLornan D, Yakoub-Agha I., Impact of donor-derived CD34"+"infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT., Bone marrow transplantation, 57, (2), 2022, p261-270
Dimopoulos MA, Richardson PG, Bahlis NJ, Grosicki S, Cavo M, Beksaç M, Legie" W, Liberati AM, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach JP, Petrucci MT, Reece D, White D, Mateos MV, Špi"ka I, Lazaroiu M, Berdeja J, Kaufman JL, Jou YM, Ganetsky A, Popa McKiver M, Lonial S, Weisel K, ELOQUENT-1 investigators., Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial., The Lancet. Haematology, 9, (6), 2022, pe403-e414
Masouridi-Levrat S, Olavarria E, Iacobelli S, Aljurf M, Morozova E, Niittyvuopio R, Sengeloev H, Reményi P, Helbig G, Browne P, Ganser A, Nagler A, Snowden JA, Robin M, Passweg J, Van Gorkom G, Wallet HL, Hoek J, Blok HJ, De Witte T, Kroeger N, Hayden P, Chalandon Y, Agha IY., Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Party of the EBMT., Bone marrow transplantation, 57, (1), 2022, p23-30
Rebecca Amet, Viola Previtali, Helene B. Mihigo, Emily Sheridan, Sarah Brophy , Nadhim Kamil Hante, Maria Jose Santos-Martinez, Patrick J. Hayden, Paul V. Browne, Isabel Rozas, Anthony M. McElligott , Daniela M. Zisterer , A novel aryl-guanidinium derivative, VP79s, targets the signal transducer and activator of transcription 3 signaling pathway, downregulates myeloid cell leukaemia-1 and exhibits preclinical activity against multiple myeloma , Life Sciences, 290, 2022
Hernández-Boluda JC, Pereira A, Zinger N, Gras L, Martino R, Nikolousis E, Finke J, Chinea A, Rambaldi A, Robin M, Saccardi R, Natale A, Snowden JA, Tsirigotis P, Vallejo C, Wulf G, Xicoy B, Russo D, Maertens J, Daguindau E, Lenhoff S, Hayden P, Czerw T, McLornan DP, Yakoub-Agha I., Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT., Bone marrow transplantation, 57, (3), 2022, p416-422
McLornan DP, Gras L, Martin I, Sirait T, Schroeder T, Blau IW, Kuball J, Byrne J, Collin M, Stadler M, Desmier D, Salmenniemi U, Jindra P, Mikhailova N, Lenhoff S, Rifón J, Robin M, Rovira M, Veelken H, Sadowska-Klasa A, Zecca M, Hayden PJ, Czerw T, Hernández-Boluda JC, Yakoub-Agha I., Outcome of allogeneic haematopoietic cell transplantation in eosinophilic disorders: A retrospective study by the chronic malignancies working party of the EBMT., British journal of haematology, 198, (1), 2022, p209-213
O'Gorman P, Laubach JP, O'Dwyer ME, Krawczyk J, Yee AJ, Gilligan O, Cahill MR, Rosenblatt J, Quinn J, Murphy PT, DiPietro H, Perera MR, Crotty GM, Cummings K, Hayden PJ, Browne P, Savell A, O'Leary HM, O'Keeffe D, Masone K, Hennessy BJ, Guerrero Garcia T, Scott K, Saeed K, Bianchi G, Dowling P, Tierney C, Richardson PG., Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma., American journal of hematology, 97, (5), 2022, p562-573
Swan D, Hayden PJ, Eikema DJ, Koster L, Sauer S, Blaise D, Nicholson E, Rabin N, Touzeau C, Byrne J, Huynh A, Cornelissen JJ, Potter V, Forcade E, Parrish C, Gribben J, Chretien ML, Mielke S, Gedde-Dahl T, Reményi P, Tsirigotis P, Garcia Guiñón A, Beksac M, Schönland S, Yakoub-Agha I., Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019., British journal of haematology, 197, (1), 2022, p82-96
Gagelmann N, Sureda A, Montoto S, Murray J, Bolaños N, Kenyon M, Beksac M, Schönland S, Hayden P, Scheurer H, Morgan K, Garderet L, McLornan DP, Ruggeri A., Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper., The Lancet. Haematology, 9, (10), 2022, pe786-e795
Onida F, Sbianchi G, Radujkovic A, Sockel K, Kröger N, Sierra J, Socié G, Cornelissen J, Poiré X, Raida L, Bourhis JH, Finke J, Passweg J, Salmenniemi U, Schouten HC, Beguin Y, Martin S, Deconinck E, Ganser A, Zver S, Lioure B, Rohini R, Koster L, Hayden P, Iacobelli S, Robin M, Yakoub-Agha I., Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP., Bone marrow transplantation, 57, (6), 2022, p896-902
Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, Chabannon C, Ciceri F, Corbacioglu S, Ellard R, Sanchez-Guijo F, Jäger U, Hildebrandt M, Hudecek M, Kersten MJ, Köhl U, Kuball J, Mielke S, Mohty M, Murray J, Nagler A, Rees J, Rioufol C, Saccardi R, Snowden JA, Styczynski J, Subklewe M, Thieblemont C, Topp M, Ispizua ÁU, Chen D, Vrhovac R, Gribben JG, Kröger N, Einsele H, Yakoub-Agha I., Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)., Annals of oncology : official journal of the European Society for Medical Oncology, 33, (3), 2022, p259-275
Chihara D, Gras L, Zinger N, Kröger N, Mayer J, Passweg J, De Latour RP, Byrne J, Krüger W, Bohn JP, Platzbecker U, Blau IW, Bonifazi F, Helbig G, McDonald A, Mistrik M, Mohty M, Ram R, Sanz J, Llamas CV, Kreitman RJ, Hayden PJ, McLornan D, Tournilhac O, Van Gelder M, Yakoub-Agha I., Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience., Haematologica, 2022
Nabergoj M, Mauff K, Beelen D, Ganser A, Kröger N, Stölzel F, Finke J, Passweg J, Cornelissen J, Schub N, Veelken JH, Beguin Y, Wilson K, Zuckerman T, Hunault-Berger M, Lioure B, Porras RP, Turlure P, Kerre T, Koster L, Hayden PJ, Onida F, Scheid C, Chalandon Y, Robin M, Yakoub-Agha I., Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: a study of the Chronic Malignancies Working Party of the EBMT., Bone marrow transplantation, 57, (7), 2022, p1072-1078
Koenecke C, Eikema DJ, Hazelaar S, Schroeder T, Potter V, Kröger N, Bornhäuser M, Finke J, Platzbecker U, Radujkovic A, Ganser A, Salmenniem U, Blaise D, Kobbe G, Meijer E, Friis L, Maertens J, Caballero D, Cornelissen JJ, Olivieri A, Gulsum O, Hayden PJ, Onida F, Robin M, Yakoub-Agha I., Prognostic value of CPSS cytogenetic risk classification in patients with CMML after allogeneic hematopoietic cell transplantation: a retrospective multicenter study of the Chronic Malignancies Working Party of the EBMT., Bone marrow transplantation, 57, (10), 2022, p1607-1611
Drozd-Soko"owska J, Gras L, Zinger N, Snowden JA, Arat M, Basak G, Pouli A, Crawley C, Wilson KMO, Tilly H, Byrne J, Bulabois CE, Passweg J, Ozkurt ZN, Schroyens W, Lioure B, Colorado Araujo M, Poiré X, Van Gorkom G, Gurman G, de Wreede LC, Hayden PJ, Beksac M, Schönland SO, Yakoub-Agha I., Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation-study on behalf of CMWP of the EBMT., Bone marrow transplantation, 57, (4), 2022, p633-640
Robin M, de Wreede LC, Padron E, Bakunina K, Fenaux P, Koster L, Nazha A, Beelen DW, Rampal RK, Sockel K, Komrokji RS, Gagelmann N, Eikema DJ, Radujkovic A, Finke J, Potter V, Killick SB, Legrand F, Solary E, Broom A, Garcia-Manero G, Rizzoli V, Hayden P, Patnaik MM, Onida F, Yakoub-Agha I, Itzykson R., Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis., Blood, 140, (12), 2022, p1408-1418
Sellner L, Schetelig J, Koster L, Choi G, Blaise D, Beelen D, Schianca FC, Passweg J, Schanz U, Gyan E, Sora F, Kröger N, Wulf GG, Van Gorkom G, Mayer J, Orvain C, Bourhis JH, Jindra P, Potter V, Zallio F, Vandenberghe E, Robinson S, Hayden PJ, Yakoub-Agha I, Montoto S, Dreger P, European Society for Blood and Marrow Transplantation Lymphoma and Chronic Malignancies Working Parties., Correction: Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey., Bone marrow transplantation, 56, (12), 2021, p3108
Hayden PJ, Eikema DJ, de Wreede LC, Koster L, Kröger N, Einsele H, Minnema M, Dominietto A, Potter M, Passweg J, Bermúdez A, Nguyen-Quoc S, Platzbecker U, Tischer J, Ciceri F, Veelken JH, Ljungman P, Schaap N, Forcade E, Carella AM, Gandemer V, Arcese W, Bloor A, Olivieri A, Vincent L, Beksac M, Schönland S, Yakoub-Agha I., Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party., Bone marrow transplantation, 56, (10), 2021, p2367-2381
Hernández-Boluda JC, Pereira A, Kröger N, Beelen D, Robin M, Bornhäuser M, Angelucci E, Vitek A, Blau IW, Niittyvuopio R, Finke J, Cornelissen JJ, Passweg J, Dreger P, Petersen E, Kanz L, Sanz J, Zuckerman T, Zinger N, Iacobelli S, Hayden P, Czerw T, McLornan D, Yakoub-Agha I., Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation., Leukemia, 35, (1), 2021, p215-224
McLornan DP, Hernandez-Boluda JC, Czerw T, Cross N, Joachim Deeg H, Ditschkowski M, Moonim MT, Polverelli N, Robin M, Aljurf M, Conneally E, Hayden P, Yakoub-Agha I., Correction: Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party., Leukemia, 35, (12), 2021, p3625
Nabergoj M, Mauff K, Robin M, Kröger N, Angelucci E, Poiré X, Passweg J, Radujkovic A, Platzbecker U, Robinson S, Rambaldi A, Petersen SL, Stölzel F, Stelljes M, Ciceri F, Mayer J, Ladetto M, de Wreede LC, Koster L, Hayden PJ, Czerw T, Hernández-Boluda JC, McLornan D, Chalandon Y, Yakoub-Agha I., Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT., Bone marrow transplantation, 56, (8), 2021, p1944-1952
McLornan DP, Sirait T, Hernández-Boluda JC, Czerw T, Hayden P, Yakoub-Agha I., European wide survey on allogeneic haematopoietic cell transplantation practice for myelofibrosis on behalf of the EBMT chronic malignancies working party., Current research in translational medicine, 69, (1), 2021, p103267
Schetelig J, Baldauf H, Koster L, Kuxhausen M, Heidenreich F, de Wreede LC, Spellman S, van Gelder M, Bruno B, Onida F, Lange V, Massalski C, Potter V, Ljungman P, Schaap N, Hayden P, Lee SJ, Kröger N, Hsu K, Schmidt AH, Yakoub-Agha I, Robin M., Corrigendum: Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia., Frontiers in immunology, 12, 2021, p813838
Fernández de Larrea C, Kyle R, Rosiñol L, Paiva B, Engelhardt M, Usmani S, Caers J, Gonsalves W, Schjesvold F, Merlini G, Lentzch S, Ocio E, Garderet L, Moreau P, Sonneveld P, Badros A, Gahrton G, Goldschmidt H, Tuchman S, Einsele H, Durie B, Wirk B, Musto P, Hayden P, Kaiser M, Miguel JS, Bladé J, Rajkumar SV, Mateos MV., Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage., Blood cancer journal, 11, (12), 2021, p192
Hernández-Boluda JC, Pereira A, Kröger N, Cornelissen JJ, Finke J, Beelen D, de Witte M, Wilson K, Platzbecker U, Sengeloev H, Blaise D, Einsele H, Sockel K, Krüger W, Lenhoff S, Salaroli A, Martin H, García-Gutiérrez V, Pavone V, Alvarez-Larrán A, Raya JM, Zinger N, Gras L, Hayden P, Czerw T, P McLornan D, Yakoub-Agha I., Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry., American journal of hematology, 96, (10), 2021, p1186-1194
Garderet L, Sbianchi G, Iacobelli S, Blaise D, Byrne JL, Remenyi P, Apperley JF, Touzeau C, Isaksson C, Browne P, Mayer J, Lenhoff S, Gonzalez Muniz S, Parody Porras R, Basak G, Poire X, Trneny M, Nagler A, Michieli M, Tanase A, Koster L, Hayden PJ, Beksac M, Schönland S, Yakoub-Agha I., Prognostic impact of early-versus-late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: Results from the CALM study by the CMWP of the EBMT., European journal of haematology, 106, (5), 2021, p708-715
McLornan DP, Hernandez-Boluda JC, Czerw T, Cross N, Joachim Deeg H, Ditschkowski M, Moonim MT, Polverelli N, Robin M, Aljurf M, Conneally E, Hayden P, Yakoub-Agha I., Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party., Leukemia, 35, (9), 2021, p2445-2459
Kröger N, Sbianchi G, Sirait T, Wolschke C, Beelen D, Passweg J, Robin M, Vrhovac R, Helbig G, Sockel K, Conneally E, Rubio MT, Beguin Y, Finke J, Bernasconi P, Morozova E, Clausen J, von dem Borne P, Schaap N, Schroyens W, Patriarca F, Di Renzo N, Ye"in ZA, Hayden P, McLornan D, Yakoub-Agha I., Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT., Leukemia, 35, (12), 2021, p3551-3560
Sahebi F, Eikema DJ, Koster L, Kroger N, Meijer E, van Doesum JA, Rovira M, Koc Y, Angelucci E, Blaise D, Sammassimo S, McDonald A, Arroyo CH, Sanchez JF, Forcade E, Castagna L, Stölzel F, Sanz J, Tischer J, Ciceri F, Valcarcel D, Proia A, Hayden PJ, Beksac M, Yakoub-Agha I, Schönland S., Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation., Transplant Cell Ther, 27, (12), 2021, p999.e1-999.e10
McLornan D, Eikema DJ, Czerw T, Kröger N, Koster L, Reinhardt HC, Angelucci E, Robin M, Bornhäuser M, Passweg J, Clark A, Vydra J, Blau IE, Niittyvuopio R, Platzbecker U, Cornelissen JJ, Chevallier P, Srour M, Stamatovic D, Martinez-Lopez J, de Wreede L, Hayden P, Hernández-Boluda JC, Yakoub-Agha I., Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis., Bone marrow transplantation, 56, (9), 2021, p2160-2172
Battipaglia G, Mauff K, Wendel L, Angelucci E, Mohty M, Arcese W, Santarone S, Rubio MT, Kroger N, Fox ML, Blaise D, Iori AP, Fanin R, Chalandon Y, Pioltelli P, Marotta G, Chiusolo P, Sever M, Solano C, Contentin N, de Wreede LC, Czerw T, Hernandez-Boluda JC, Hayden P, McLornan D, Yakoub-Agha I., Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT., Bone marrow transplantation, 56, (7), 2021, p1593-1602
Polverelli N, Mauff K, Kröger N, Robin M, Beelen D, Beauvais D, Chevallier P, Mohty M, Passweg J, Rubio MT, Maertens J, Finke J, Bornhäuser M, Vrhovac R, Helbig G, Mear JB, Castagna L, Reményi P, Angelucci E, Karakasis D, Rifòn J, Sirait T, Russo D, de Wreede L, Czerw T, Hernández-Boluda JC, Hayden P, McLornan D, Yakoub-Agha I., Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT)., American journal of hematology, 96, (1), 2021, p69-79
Morris C, Chabannon C, Masszi T, Russell N, Nahi H, Kobbe G, Krejci M, Auner HW, Pohlreich D, Hayden P, Basak GW, Lenhoff S, Schaap N, van Biezen A, Knol C, Iacobelli S, Liu Q, Celanovic M, Garderet L, Kröger N., Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor., Bone marrow transplantation, 55, (2), 2020, p356-366
Schetelig J, Baldauf H, Koster L, Kuxhausen M, Heidenreich F, de Wreede LC, Spellman S, van Gelder M, Bruno B, Onida F, Lange V, Massalski C, Potter V, Ljungman P, Schaap N, Hayden P, Lee SJ, Kröger N, Hsu K, Schmidt AH, Yakoub-Agha I, Robin M., Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia., Frontiers in immunology, 11, 2020, p584520
Yakoub-Agha I, Chabannon C, Bader P, Basak GW, Bonig H, Ciceri F, Corbacioglu S, Duarte RF, Einsele H, Hudecek M, Kersten MJ, Köhl U, Kuball J, Mielke S, Mohty M, Murray J, Nagler A, Robinson S, Saccardi R, Sanchez-Guijo F, Snowden JA, Srour M, Styczynski J, Urbano-Ispizua A, Hayden PJ, Kröger N., Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)., Haematologica, 105, (2), 2020, p297-316
Sellner L, Schetelig J, Koster L, Choi G, Blaise D, Beelen D, Schianca FC, Passweg J, Schanz U, Gyan E, Sora F, Kröger N, Wulf GG, Van Gorkom G, Mayer J, Orvain C, Bourhis JH, Jindra P, Potter V, Zallio F, Vandenberghe E, Robinson S, Hayden PJ, Yakoub-Agha I, Montoto S, Dreger P, on behalf of the European Society for Blood and Marrow Transplantation Lymphoma and Chronic Malignancies Working Parties., Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey., Bone marrow transplantation, 55, (12), 2020, p2335-2338
Beauvais D, Danhof S, Hayden PJ, Einsele H, Yakoub-Agha I., Clinical data, limitations and perspectives on chimeric antigen receptor T-cell therapy in multiple myeloma., Current opinion in oncology, 32, (5), 2020, p418-426
Garderet L, Morris C, Beksac M, Gahrton G, Schönland S, Yakoub-Agha I, Hayden PJ., Are Autologous Stem Cell Transplants Still Required to Treat Myeloma in the Era of Novel Therapies? A Review from the Chronic Malignancies Working Party of the EBMT., Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 26, (9), 2020, p1559-1566
Hayden PJ, Iacobelli S, Pérez-Simón JA, van Biezen A, Minnema M, Niittyvuopio R, Schönland S, Meijer E, Blaise D, Milpied N, Márquez-Malaver FJ, Veelken JH, Maertens J, Michallet M, Cammenga J, N'Guyen S, Niederwieser D, Hunault-Berger M, Bourhis JH, Passweg J, Bermudez A, Chalandon Y, Yakoub-Agha I, Garderet L, Kröger N., Conditioning-based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991-2012) on behalf of EBMT CMWP., European journal of haematology, 104, (3), 2020, p181-189
Weisel K, Dimopoulos M, Moreau P, Yagci M, Larocca A, Kanate AS, Vural F, Cascavilla N, Basu S, Johnson P, Byeff P, Hus M, Rodríguez-Otero P, Muelduer E, Anttila P, Hayden PJ, Krauth MT, Lucio P, Ben-Yehuda D, Mendeleeva L, Guo S, Yu X, Grote L, Biyukov T, Dhanasiri S, Richardson P., Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma., Leukemia & lymphoma, 61, (8), 2020, p1850-1859
McLornan DP, Malpassuti V, Lippinkhof-Kozijn A, Potter V, Beelen D, Bunjes D, Sengeloev H, Radujkovic A, Passweg J, Chalandon Y, Kröger N, Wulf GG, Johansson JE, Ciceri F, Bornhäuser M, Holler E, Guffroy B, Martin S, Neubauer A, Gramatski M, Robin M, Iacobelli S, Hayden P, Hernández Boluda JC, Czerw T, Yakoub-Agha I., Outcome of allogeneic haematopoietic stem cell transplantation in myeloproliferative neoplasm, unclassifiable: a retrospective study by the Chronic Malignancies Working Party of the EBMT., British journal of haematology, 190, (3), 2020, p437-441
Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M, OPTIMISMM trial investigators., Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial., The Lancet. Oncology, 20, (6), 2019, p781-794
Brodie R, Langabeer SE, Quinn J, McMenamin ME, Hayden PJ., Sorafenib for relapsed FLT3-ITD-positive acute myeloid leukemia postallogeneic stem cell transplantation presenting as leukemia cutis., Clinical case reports, 7, (12), 2019, p2579-2580
McLornan D, Szydlo R, Koster L, Chalandon Y, Robin M, Wolschke C, Beelen D, Socié G, Bornhäuser M, Angelucci E, Niederwieser D, Gerbitz A, Finke J, Vitek A, Itälä-Remes M, Radujkovic A, Kanz L, Potter V, Chevallier P, Stelljes M, Petersen E, Robinson S, Poiré X, Klyuchnikov E, Hernández-Boluda JC, Czerw T, Hayden P, Kröger N, Yakoub-Agha I., Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation., Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 25, (11), 2019, p2167-2171
Hayden PJ, Sirait T, Koster L, Snowden JA, Yakoub-Agha I., An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT., Current research in translational medicine, 67, (3), 2019, p79-88
Broderick V, Waghorn K, Langabeer SE, Jeffers M, Cross NCP, Hayden PJ., Molecular response to imatinib in KIT F522C-mutated systemic mastocytosis., Leukemia research, 77, 2019, p28-29
Breitkreutz I, Podar K, Figueroa-Vazquez V, Wilhelm S, Hayden PJ, Anderson KC, Raab MS., The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma., Annals of hematology, 97, (5), 2018, p839-849
Douglas KW, Gilleece M, Hayden P, Hunter H, Johnson PRE, Kallmeyer C, Malladi RK, Paneesha S, Pawson R, Quinn M, Raj K, Richardson D, Robinson S, Russell N, Snowden J, Sureda A, Tholouli E, Thomson K, Watts M, Wilson KM., UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy., Journal of clinical apheresis, 33, (1), 2018, p46-59
Elhassadi E, Flavin R, Browne P, Conneally E, Hayden P, Quinn F, Higgins E, Vandenberghe E, Transformed follicular lymphoma (tFL): consolidation therapy may improve survival, Irish Journal of Medical Science, 1863, 2017, p589-595
Langabeer SE, Haslam K, O'Brien D, Kelly J, Andrews C, Ryan C, Flavin R, Hayden PJ, Bacon CL, Acute Lymphoblastic Leukemia Arising in CALR Mutated Essential Thrombocythemia., Case reports in hematology, 2016
Lavin M, Brophy T.M, Rawley O, O'Sullivan J.M, Hayden P.J, Browne P.V, Ryan K, O'Connell N, O'Donnell J.S, Lenalidomide as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy, Journal of Thrombosis and Haemostasis, 14, (6), 2016, p1200 - 1205
O'Kane G, Bracken-Clarke D, Gardiner N, Lee G, Ni Chonghaile M, Power D, Daly PA, McCaffrey J, Bacon CL, Conneally E, Flynn C, Vandenberghe E, Kennedy MJ, Browne PV, O'Donnell DM, Hayden PJ, A single-centre analysis of 30 patients with relapsed germ cell tumours treated with the TI-CE regimen., 2016
Lehners N, Hayden PJ, Goldschmidt H, Raab MS., Management of high-risk Myeloma: an evidence-based review of treatment strategies., Expert review of hematology, 9, (8), 2016, p753-765
Smyth L, Browne PV, Conneally E, Flynn C, Hayden P, Jeffers M, O'Brien D, Quinn F, Kelly J, Perera M, Crotty GM, Leahy M, Hennessy B, Jackson F, Ryan M, Vandenberghe E, Burkitt leukaemia/lymphoma: R-CODOX-M/R-IVAC remains gold standard treatment in BL., 2016
Appleby N, Dillon A, Arrigan M, Fennell J, Crowley B, Hayden PJ, Enright H, Symptomatic BK virus reactivation following fludarabine, cyclophosphamide and rituximab chemotherapy for chronic lymphocytic leukemia/small lymphocytic lymphoma., Leukemia and Lymphoma, 55, (5), 2014, p1181 - 1183
Conlon, N.P., Hayden, P., Barnes, L., Doran, M., O'Shea, F., Feigher, C., Schnitzler's syndrome; a case highlighting the complications of long-standing acquired autoinflammation, European Journal of Dermatology, 24, (3), 2014, p405-406
Liptrot S, O' Brien D, Langabeer SE, Quinn F, Mackarel AJ, Elder P, Vandenberghe E, Hayden PJ, An immunophenotypic and molecular diagnosis of composite hairy cell leukaemia and chronic lymphocytic leukaemia., 2013
Scott K, Hayden PJ, Howman A, Wheatley K, Coyne I. , Bortezomib for the treatment of multiple myeloma , Cochrane Database of Systematic Reviews Issue 11. Art. No.: CD010816. , (Issue 11. ), 2013
Fahy CM, Fortune A, Quinn F, McMenamin ME, Browne PV, Langabeer S, McCarron S, Hayden P, Marren P, Ni Chonghaile M, Irvine AD, Vandenberghe E, Barnes L, Development of mycosis fungoides after bone marrow transplantation for chronic myeloid leukaemia; transmission from allogeneic donor., The British journal of dermatology, 2013
Langabeer SE, O'Brien D, Liptrot S, Flynn CM, Hayden PJ, Conneally E, Browne PV, Vandenberghe E, Correlation of the BRAF V600E mutation in hairy cell leukaemia with morphology, cytochemistry and immunophenotype., International Journal of laboratory Hematology, 34, (4), 2012, p417-21
Raab MS, Breitkreutz I, Anderhub S, Rønnest MH, Leber B, Larsen TO, Weiz L, Konotop G, Hayden PJ, Podar K, Fruehauf J, Nissen F, Mier W, Haberkorn U, Ho AD, Goldschmidt H, Anderson KC, Clausen MH, Krämer A., GF-15, a novel inhibitor of centrosomal clustering, suppresses tumor cell growth in vitro and in vivo., Cancer research, 72, (20), 2012, p5374-5385
Douglas KW, Parker AN, Hayden PJ, Rahemtulla A, D'Addio A, Lemoli RM, Rao K, Maris M, Pagliuca A, Uberti J, Scheid C, Noppeney R, Cook G, Bokhari SW, Worel N, Mikala G, Masszi T, Masszi T, Taylor R, Treisman J., Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA., Bone marrow transplantation, 47, (1), 2012, p18-23
Tewari P, Ryan AW, Hayden PJ, Catherwood M, Drain S, Staines A, Grant T, Nieters A, Becker N, de Sanjose S, Foretova L, Maynardie M, Cocco P, Boffetta P, Brennan P, Chanock S, Lawler M, Browne PV., Genetic variation at the 8q24 locus confers risk to multiple myeloma., British journal of haematology, 156, (1), 2012, p133-136
McCarron SL, Kelly J, Coen N, McCabe S, Fay M, O'Dwyer M, Hayden PJ, Langabeer SE., A novel e8a2 BCR-ABL1 fusion with insertion of RALGPS1 exon 8 in a patient with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia., Leukemia & lymphoma, 52, (5), 2011, p919-921
Maginn EN, Browne PV, Hayden P, Vandenberghe E, McDonagh B, Evans P, Goodyer M, Tewari P, Campiani G, Butini S, Williams DC, Zisterer DM, Lawler MP, McElligott AM., PBOX-15, a novel microtubule targeting agent, induces apoptosis, upregulates death receptors, and potentiates TRAIL-mediated apoptosis in multiple myeloma cells., British Journal of Cancer, 104, (2), 2011, p281 - 289
McMillin DW, Delmore J, Negri J, Buon L, Jacobs HM, Laubach J, Jakubikova J, Ooi M, Hayden P, Schlossman R, Munshi NC, Lengauer C, Richardson PG, Anderson KC, Mitsiades CS., Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications., British journal of haematology, 152, (4), 2011, p420-432
Meenaghan T, O'Dwyer M, Hayden P, Hayat A, Murray M, Dowling M., Home administration of bortezomib: making a difference to myeloma patients' lives., European journal of oncology nursing : the official journal of European Oncology Nursing Society, 14, (2), 2010, p134-136
Krawczyk J, Ansar N, Swords R, Murphy T, MacDonagh B, Meenaghan T, Hayden P, Hayad A, Murray M, O'Dwyer M., Clofarabine in the treatment of poor risk acute myeloid leukaemia., Hematological oncology, 28, (3), 2010, p118-123
Ooi MG, Hayden PJ, Kotoula V, McMillin DW, Charalambous E, Daskalaki E, Raje NS, Munshi NC, Chauhan D, Hideshima T, Buon L, Clynes M, O'Gorman P, Richardson PG, Mitsiades CS, Anderson KC, Mitsiades N., Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib., Clinical cancer research : an official journal of the American Association for Cancer Research, 15, (23), 2009, p7153-7160
Raab MS, Breitkreutz I, Tonon G, Zhang J, Hayden PJ, Nguyen T, Fruehauf JH, Lin BK, Chauhan D, Hideshima T, Munshi NC, Anderson KC, Podar K., Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling., Blood, 113, (7), 2009, p1513-1521
McMillin DW, Ooi M, Delmore J, Negri J, Hayden P, Mitsiades N, Jakubikova J, Maira SM, Garcia-Echeverria C, Schlossman R, Munshi NC, Richardson PG, Anderson KC, Mitsiades CS., Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235., Cancer research, 69, (14), 2009, p5835-5842
Waterhouse DF, Moloney GA, Gargoum FS, Hayden PS, O'Gorman T., Extramedullary relapse of IgA-lambda myeloma after recent bortezomib therapy: a case report., Cases journal, 2, 2009, p7456
Negri JM, McMillin DW, Delmore J, Mitsiades N, Hayden P, Klippel S, Hideshima T, Chauhan D, Munshi NC, Buser CA, Pollard J, Richardson PG, Anderson KC, Mitsiades CS., In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465., British journal of haematology, 147, (5), 2009, p672-676
Mitsiades CS, Hayden PJ, Anderson KC, Richardson PG., From the bench to the bedside: emerging new treatments in multiple myeloma., Best practice & research. Clinical haematology, 20, (4), 2007, p797-816
Mitsiades CS, Hayden P, Kotoula V, McMillin DW, McMullan C, Negri J, Delmore JE, Poulaki V, Mitsiades N., Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition., The Journal of clinical endocrinology and metabolism, 92, (12), 2007, p4845-4852
Hayden PJ, Tewari P, Morris DW, Staines A, Crowley D, Nieters A, Becker N, de Sanjose S, Foretova L, Maynadie M, Cocco PL, Boffetta P, Brennan P, Chanock SJ, Browne PV, Lawler M., Variation in DNA repair genes XRCC3, XRCC4, XRCC5 and susceptibility to myeloma., Human Molecular Genetics, 16, (24), 2007, p3117 - 3127
Hayden PJ, Mitsiades CS, Anderson KC, Richardson PG., Novel therapies in myeloma., Current opinion in hematology, 14, (6), 2007, p609-615
O'Donghaile D, Hayden PJ, McCarron SL, Doyle EM, Lawler M, Browne PV, Conneally E, Vandenberghe E, McCann SR, Marrow aplasia developing 13 years after HLA-identical sibling allogeneic transplantation for chronic myeloid leukaemia: successful treatment with antithymocyte globulin and peripheral blood stem cell infusion from the original donor., European journal of haematology, 76, (3), 2006, p258-60
Ní Ainle F, Hayden PJ, Crosby P, Murphy K, McCarthy D, Kelly J, Neat MJ., Concurrent rearrangement of BCL1 and BCL6 with a single immunoglobulin locus in a case of diffuse large B-cell lymphoma., Leukemia & lymphoma, 47, (12), 2006, p2655-2656
Hayden PJ, O'Connell NM, O'Brien DA, O'Rourke P, Lawlor E, Browne PV, The value of autofluorescence as a diagnostic feature of acute promyelocytic leukemia., Haematologica, 2006
Hayden PJ, O'Driscoll A, Gardiner N, Swords R, Sargent J, Ni Ainghle F, Fortune A, Murphy PT, Leahy M, Jackson F, Ryan M, Hennessy B, Cahill M, Crotty G, Enright H, Conneally E, Vandenberghe E, McCann SR and Browne PV. , Autologous stem cell transplantation in myeloma: the St James's Hospital experience, 1997-2003., Irish Journal of Medical Science, Apr-June 174, (2), 2005, p26 - 32
Hayden PJ, Crampe M, Lawler M, Conneally E, McCann SR, Vandenberghe E, Browne PV., Use of DLI to achieve complete donor chimerism in a patient receiving systemic immunosuppression for refractory AIHA post-NST., Bone Marrow Transplantation, 36, 2005, p735 - 736
Swords R, Hayden PJ, Molloy K, Lawler M, Browne PV, Murphy PT., Successful induction of molecular remission with single-agent anti-CD33 antibody (gemtuzumab ozogamicin) in chemotherapy-refractory relapse of acute myeloid leukaemia post-BMT., European Journal of Haematology, 73, (6), 2004, p450-451
P. J. Hayden, N. Gardiner, K. Molloy, J. Ryan, M. Lawler and S. R. McCann, Pure red cell aplasia after a major ABO-mismatched bone marrow transplant for chronic myeloid leukaemia: response to re-introduction of cyclosporin, Bone Marrow Transplantation, 33, (4), 2004, p459-461
Hayden PJ, Keogh F, Ni Conghaile M, Carroll M, Crowley M, Fitzsimon N, Gardiner N, Vandenberghe E, O'Riordan J, McCann SR, A single-centre assessment of long-term quality-of-life status after sibling allogeneic stem cell transplantation for chronic myeloid leukaemia in first chronic phase., 2004
Crowley J, Hagan R, Clancy D, Rooney G, Dunne C, Lawlor E, Hayden P, Little AM, Soteriou B, Marsh SG, Madrigal JA., Two sets of HLA Class II DRB and DQB1 alleles co-segregate among family members in a single maternal haplotype., Tissue antigens, 61, (6), 2003, p487-491
Hayden, PJ, O'Brien, M, Collins, B, O'Farrelly, C, Murphy, K, Inherited thrombotic tendency in a pedigree with antithrombin La Rochelle (N405K) and factor V Leiden., Clinical and laboratory haematology, 25, (3), 2003, p191 - 193